2024-03-06 20:39:28 ET
Summary
- Fennec released sales guidance for Q4 2023, exceeded analyst expectations.
- A pending EU launch of PEDMARK® provides a near term opportunity for the Company to finalize an EU partnership.
- Revenue growth in the US, and completion of a Japanese bridging study provide opportunities for further geographic partnerships, or a sale of the Company.
Fennec Pharmaceuticals – Revenue Guidance and EU Launch
Fennec Pharmaceuticals ( FENC ) (the Company), is a small cap, commercial-stage biotech company with a single drug, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate specifically developed for pediatric patients. PEDMARK is FDA-approved to reduce the risk of ototoxicity or hearing loss associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. The drug is used in children who receive platinum-based chemotherapy....
Read the full article on Seeking Alpha
For further details see:
Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price